I had claude create a protocol only using fda approved drugs.
    1/10/2026

    From the encyclopedia
    Minoxidil →

    An essential vasodilator with some anti-androgenic effects

    Finasteride →

    Frontline, gold standard treatment for combatting androgenic alopecia

    Cetirizine →

    popular antihistamine showing promise for hair loss as an anti-inflammatory and prostaglandin inhibitor

    At a glance
    In this hair loss treatment regimen post, the primary subjects mentioned are
    💧 Minoxidil (topical) 5% daily
    💧 Finasteride (topical) 0.05% daily
    💧 Tacrolimus (topical) 0.1% daily
    💧 Cetirizine (topical) 1% daily
    💧 Bimatoprost (topical) 0.03% weekly
    💧 Lithium gluconate (topical) 8% weekly
    💧 Losartan (topical) 0.5% weekly
    💧 Melatonin (topical) 0.1% daily
    💧 NAC (topical) 5% weekly
    💧 Caffeine (topical) 2% daily
    💧 Tretinoin (topical) 0.025% weekly
    the tone is 😐 neutral with 60-75% improvement results.

    Other terms

    A new hair loss protocol using FDA-approved topical treatments targets eight pathways, potentially improving results by 60-75% compared to the standard 40-50% from oral minoxidil and finasteride. The protocol includes minoxidil, finasteride, tacrolimus, cetirizine, bimatoprost, lithium gluconate, losartan, melatonin, NAC, caffeine, and tretinoin, with a monthly cost of $35-50 in Mexico and $80-150 in the US.
    View this post in the Community →

    Similar Community Posts Join

    5 / 5 results

    Related Research

    6 / 6 results

      research ZALCITABINE

      January 2004
      This abstract lists numerous dermatological side effects and reactions associated with various medications but reports no new research findings.
      Medications

      research Medications

      January 2016 in “Springer eBooks”
      This review discusses medications used in dermatology, detailing their side effects and interactions, and reports no new clinical results.
      New Changes in Pregnancy and Lactation Labeling: Review of Dermatologic Drugs

      research New changes in pregnancy and lactation labelling: Review of dermatologic drugs

      16 citations , May 2019 in “International Journal of Women's Dermatology”
      This study reviewed and categorized dermatological drugs for pregnancy and lactation according to new FDA labeling guidelines, which replaced simplistic letter categories with detailed information, aiming to improve prescribing decisions by addressing both maternal and paternal reproductive potential.
      Management of Primary Cicatricial Alopecias: Options for Treatment

      research Management of primary cicatricial alopecias: options for treatment

      98 citations , May 2008 in “British Journal of Dermatology”
      This review discusses evidence-based guidance for managing primary cicatricial alopecias but reports no new clinical results, highlighting significant gaps in knowledge and the need for more quality trials.
      Chemically Induced Hair Loss/Alopecia

      research Chemically Induced Hair Loss/Alopecia

      January 2019 in “Springer eBooks”
      This review discusses drugs and mechanisms possibly responsible for chemical- and drug-induced hair loss but presents no new research findings.